BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BNTX BioNTech SE

已收盘 04-25 16:00:00 EDT

86.71

-1.38

-1.57%

盘后86.28

-0.43-0.49%

19:52 EDT

最高88.24	最低86.13	成交量43.81万
今开87.98	昨收88.09	日振幅2.40%
总市值208.96亿	流通市值78.20亿	总股本2.41亿
成交额3,802万	换手率0.49%	流通股本9,019万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":86.71,"timestamp":1714075200000,"preClose":88.09,"halted":0,"volume":438099,"hourTrading":{"tag":"盘后","latestPrice":86.2813,"preClose":86.71,"latestTime":"19:52 EDT","volume":4343,"amount":376542.4158,"timestamp":1714089145873},"delay":0,"floatShares":90185753,"shares":240990499,"eps":4.233448,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.38,"latestTime":"04-25 16:00:00 EDT","open":87.98,"high":88.24,"low":86.13,"amount":38015948.72421,"amplitude":0.023953,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.233448,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714118400000},"adr":0,"listingDate":1570680000000,"adjPreClose":88.09,"adrRate":1,"preHourTrading":{"tag":"盘前","latestPrice":87.51,"preClose":88.09,"latestTime":"09:28 EDT","volume":4549,"amount":400484.58906,"timestamp":1714051716568},"postHourTrading":{"tag":"盘后","latestPrice":86.2813,"preClose":86.71,"latestTime":"19:52 EDT","volume":4343,"amount":376542.4158,"timestamp":1714089145873},"volumeRatio":0.657994},"requestUrl":"/m/hq/s/BNTX","defaultTab":"news","newsList":[{"id":"2430323586","title":"BUZZ-辉瑞、BioNTech 因葛兰素史克起诉 COVID-19 疫苗技术而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430323586","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430323586?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:50","pubTimestamp":1714060208,"startTime":"0","endTime":"0","summary":"    4月25日 - ** 疫苗生产商辉瑞  和BioNTech  的股价下跌2%至3%。** 制药商葛兰素史克  起诉  BNTX和PFE，指控它们侵犯了其与信使核糖核酸 技术有关的专利，该技术应用于这两家公司的大片COVID-19疫苗中。** 葛兰素史克称，PFE 和 BNTX 的 Comirnaty 疫苗侵犯了其在 mRNA 疫苗创新方面的专利权，这些创新是在 COVID-19 大流行爆发 \"十多年前 \"开发的。** 葛兰素史克还要求特拉华州联邦法院向这两家公司支付数额不详的赔偿金，其中包括持续的专利许可费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430428593","title":"葛兰素史克就 Covid-19 疫苗技术起诉辉瑞和 BioNTech","url":"https://stock-news.laohu8.com/highlight/detail?id=2430428593","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430428593?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:35","pubTimestamp":1714052123,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) Blake Brittain    路透社4月25日 - 葛兰素史克公司  周四在特拉华州联邦法院起诉辉瑞  和BioNTech  ，指控它们侵犯了葛兰素史克公司与信使RNA(mRNA) 技术有关的专利权，这些技术应用于这两家公司的大片COVID-19疫苗中。葛兰素史克在诉讼中说，辉瑞和 BioNTech 的 Comirnaty 疫苗侵犯了该公司在 mRNA 疫苗创新方面的专利权，而这些创新是在 COVID-19 大流行爆发 \"十多年前 \"开发的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428313746","title":"HC Wainwright & Co.：重申BioNTech(BNTX.US)评级，由买入调整至买入评级, 目标价107.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428313746","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428313746?lang=zh_cn&edition=full","pubTime":"2024-04-17 18:35","pubTimestamp":1713350149,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申BioNTech(BNTX.US)评级，由买入调整至买入评级, 目标价107.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171835518b2e894d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171835518b2e894d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422238610","title":"药明生物2023年业绩稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2422238610","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422238610?lang=zh_cn&edition=full","pubTime":"2024-03-26 22:57","pubTimestamp":1711465020,"startTime":"0","endTime":"0","summary":"2023年业务亮点  尽管新冠疫情后面临严峻的宏观环境挑战，集团凭借独特的CRDMO商业模式和成功实施\"跟随并赢得分子\"战略，依然保持业务稳健增长。截至2023年12月31日，集团包括未完成服务订单和里程碑付款在内的未完成订单总额达206亿美元。临床后期和商业化生产收益增长至人民币77.3亿元，占2023年总收益的45.4%，延续集团临床后期和商业化生产业务加速增长势头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4371111_ZH71111_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422592487","title":"更新 1-BioNTech 因拖欠 COVID 疫苗版税而收到美国机构通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2422592487","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422592487?lang=zh_cn&edition=full","pubTime":"2024-03-25 18:47","pubTimestamp":1711363674,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (在第 2-3 段增加了细节和背景)    路透社3月25日 - BioNTech   周一称，美国国立卫生研究院已向这家德国公司发出通知，要求其支付与COVID-19疫苗相关的版税和其他款项。BioNTech公司与美国制药巨头辉瑞公司（Pfizer   ）合作生产的COVID-19疫苗引发了特许权使用费支付纠纷。但该公司表示，它不同意美国国立卫生研究院的立场，并打算对所有违约指控进行抗辩。美国国立卫生研究院的发言人没有立即回应路透社的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420174793","title":"Biontech Se盘中异动 股价大跌7.42%报87.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420174793","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420174793?lang=zh_cn&edition=full","pubTime":"2024-03-20 21:31","pubTimestamp":1710941510,"startTime":"0","endTime":"0","summary":"北京时间2024年03月20日21时31分，Biontech Se股票出现波动，股价快速跳水7.42%。截至发稿，该股报87.14美元/股，成交量36.743万股，换手率0.15%，振幅2.98%。Biontech Se股票所在的生物技术行业中，整体跌幅为0.41%。Biontech Se公司简介：BioNTech 是一家总部位于德国的生物技术公司，专注于开发癌症疗法，包括个体化免疫疗法以及COVID-19等传染病疫苗。BioNTech 与多家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320213150879d6248&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320213150879d6248&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420671912","title":"盈利暴跌后，BioNTech 寄希望于癌症药物的上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2420671912","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420671912?lang=zh_cn&edition=full","pubTime":"2024-03-20 18:15","pubTimestamp":1710929704,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社柏林3月20日 - 德国生物技术公司（BioNTech   ）与辉瑞公司（Pfizer   ）合作生产的COVID-19疫苗在流感大流行期间被广泛使用。这家总部位于美因茨的公司公布的收入为 38.19 亿欧元，比 2022 年下降了四分之三以上，净利润为 9.303 亿欧元，比上年同期下降了 90%。BioNTech公司在一份声明中表示，2024年的目标收入为25亿至31亿欧元，这主要取决于监管方面的发展和COVID-19疫苗的吸收情况。声明还说，该公司的目标是在 2026 年首次推出肿瘤药物，并在 2030 年之前批准十项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420490021","title":"“复必泰”开发商BioNTech(BNTX.US)加入新加坡BioPIPS联盟","url":"https://stock-news.laohu8.com/highlight/detail?id=2420490021","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420490021?lang=zh_cn&edition=full","pubTime":"2024-03-18 12:26","pubTimestamp":1710735960,"startTime":"0","endTime":"0","summary":"新加坡科技研究局和新加坡经济发展局今早发表联合公告，指全球免疫疗法公司BioNTech加入新加坡生物制药创新计划联盟，有助于加强当地生物制剂生产领域的生产力和可持续性。现有的联盟成员包括全球制药公司葛兰素史克和赛诺菲，以及新加坡的研究机构和高等教育机构如科研局、新加坡南洋理工大学、新加坡国立大学和新加坡理工大学。在新冠疫情大流行期间，由辉瑞/BioNTech联合开发的“复必泰”新冠疫苗被多国采购，BioNTech声名鹊起。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20231101162245490_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20231101162245490_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1334173/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2418705365","title":"Biontech Se盘中异动 早盘股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2418705365","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418705365?lang=zh_cn&edition=full","pubTime":"2024-03-11 22:21","pubTimestamp":1710166908,"startTime":"0","endTime":"0","summary":"北京时间2024年03月11日22时21分，Biontech Se股票出现波动，股价快速上涨5.11%。截至发稿，该股报95.93美元/股，成交量20.5388万股，换手率0.09%，振幅5.31%。Biontech Se股票所在的生物技术行业中，整体跌幅为0.19%。Biontech Se公司简介：BioNTech 是一家总部位于德国的生物技术公司，专注于开发癌症疗法，包括个体化免疫疗法以及COVID-19等传染病疫苗。BioNTech 与多家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240311222148861dd19c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240311222148861dd19c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417741634","title":"小菜园赴港IPO：业绩逆势增长 竞争日益加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2417741634","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2417741634?lang=zh_cn&edition=full","pubTime":"2024-03-06 07:12","pubTimestamp":1709680320,"startTime":"0","endTime":"0","summary":"《经济参考报》记者注意到，深耕大众便民中式餐饮的小菜园，最近两三年业绩逆势增长。　　出乎意料的是，小菜园往绩记录期间主要业绩却实现了超过行业水平的逆势大增。而净利润方面，小菜园近年来的表现更为亮眼。此外，报告期各期，小菜园的毛利率分别为65.5%、66.1%和68.6%，呈持续攀升态势。　　谈及行业竞争时，小菜园称，我国餐饮业的激烈竞争可能阻碍公司提升或保持收入及盈利能力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-03-06/doc-inamisvu9279593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-03-06/doc-inamisvu9279593.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2413277484","title":"Atossa Therapeutics Inc盘中异动 早盘快速下挫6.75%报0.951美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413277484","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413277484?lang=zh_cn&edition=full","pubTime":"2024-02-21 23:41","pubTimestamp":1708530101,"startTime":"0","endTime":"0","summary":"北京时间2024年02月21日23时41分，Atossa Therapeutics Inc股票出现波动，股价快速下挫6.75%。Atossa Therapeutics Inc股票所在的生物技术行业中，整体跌幅为0.14%。Atossa Therapeutics Inc公司简介：Atossa Therapeutics Inc 是一家临床阶段的生物制药公司，在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。该公司正在开发的治疗乳腺癌和其他乳腺疾病的药物是 Endoxifen。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240221234141861d71dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240221234141861d71dc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411892512","title":"医疗设备制造商 West Pharmaceutical 预计全年业绩疲软","url":"https://stock-news.laohu8.com/highlight/detail?id=2411892512","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411892512?lang=zh_cn&edition=full","pubTime":"2024-02-15 20:09","pubTimestamp":1707998941,"startTime":"0","endTime":"0","summary":"由于 COVID-19 疫苗和相关疗法的需求下降，该公司最近几个季度的销售额受到打击。\"West Pharmaceutical 首席执行官埃里克-格林说：\"2024 年，随着我们对库存管理时机的把握，尤其是对我们最大客户的管理，我们预计有机销售额的增长将有所放缓。West Pharmaceutical 预测 2024 年调整后每股收益在 7.50 美元至 7.75 美元之间，预期为 8.79 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411976585","title":"Atossa Therapeutics Inc盘中异动 早盘股价大涨5.15%报1.020美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411976585","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411976585?lang=zh_cn&edition=full","pubTime":"2024-02-14 23:50","pubTimestamp":1707925832,"startTime":"0","endTime":"0","summary":"北京时间2024年02月14日23时50分，Atossa Therapeutics Inc股票出现异动，股价快速上涨5.15%。Atossa Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.90%。其相关个股中，Engene Holdings Inc C/Wts 31/10/2028  Cl A、Engene Holdings Inc、Cogent Biosciences Inc涨幅较大，Kintara Therapeutics Inc、Azitra Inc、Transcode Therapeutics Inc较为活跃，换手率分别为53.40%、31.61%、30.30%，振幅较大的相关个股有Engene Holdings Inc C/Wts 31/10/2028  Cl A、Engene Holdings Inc、Renovaro Biosciences Inc，振幅分别为208.62%、51.31%、39.06%。Atossa Therapeutics Inc公司简介：Atossa Therapeutics Inc 是一家临床阶段的生物制药公司，在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240214235032861d53e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240214235032861d53e0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2410082830","title":"Atossa Therapeutics Inc盘中异动 股价大涨5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2410082830","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2410082830?lang=zh_cn&edition=full","pubTime":"2024-02-12 22:40","pubTimestamp":1707748851,"startTime":"0","endTime":"0","summary":"北京时间2024年02月12日22时40分，Atossa Therapeutics Inc股票出现波动，股价急速上涨5.80%。Atossa Therapeutics Inc股票所在的生物技术行业中，整体跌幅为0.43%。Atossa Therapeutics Inc公司简介：Atossa Therapeutics Inc 是一家临床阶段的生物制药公司，在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021222405187e6fc70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021222405187e6fc70&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405442271","title":"Biontech Se跌0.39% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2405442271","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2405442271?lang=zh_cn&edition=full","pubTime":"2024-01-24 22:58","pubTimestamp":1706108303,"startTime":"0","endTime":"0","summary":"北京时间2024年01月24日22时58分，Biontech Se股票出现异动，股价大幅下跌0.39%。截至发稿，该股报99.90美元/股，成交量3.4902万股，换手率0.01%，振幅1.07%。Biontech Se股票所在的生物技术行业中，整体跌幅为0.35%。Biontech Se公司简介：BioNTech 是一家总部位于德国的生物技术公司，专注于开发癌症疗法，包括个体化免疫疗法以及COVID-19等传染病疫苗。BioNTech 与多家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401242258237a3e0b47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401242258237a3e0b47&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2404536435","title":"Atossa Therapeutics Inc盘中异动 早盘股价大涨5.08%报0.865美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2404536435","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2404536435?lang=zh_cn&edition=full","pubTime":"2024-01-18 22:36","pubTimestamp":1705588606,"startTime":"0","endTime":"0","summary":"北京时间2024年01月18日22时36分，Atossa Therapeutics Inc股票出现异动，股价急速拉升5.08%。Atossa Therapeutics Inc股票所在的生物技术行业中，整体跌幅为0.87%。其相关个股中，Celularity Inc、Biocardia Inc C/Wts 06/08/2024、Apollomics Inc C/Wts 01/04/2028 涨幅较大，Kintara Therapeutics Inc、Transcode Therapeutics Inc、Zyversa Therapeutics Inc较为活跃，换手率分别为56.22%、40.84%、16.87%，振幅较大的相关个股有Celularity Inc、Acelyrin Inc、Transcode Therapeutics Inc，振幅分别为19.38%、17.61%、14.81%。Atossa Therapeutics Inc公司简介：Atossa Therapeutics Inc 是一家临床阶段的生物制药公司，在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024011822364687e664d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024011822364687e664d2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2404588204","title":"先声药业(02096)：《新英格兰医学杂志》发表抗新冠创新药先诺欣®治疗轻中度COVID-19成年患者的II/III期临床研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2404588204","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2404588204?lang=zh_cn&edition=full","pubTime":"2024-01-18 19:53","pubTimestamp":1705578821,"startTime":"0","endTime":"0","summary":"该研究的成功发表，标志着先诺欣成为首个成功打造完整证据链的国产3CL靶点抗新冠药物。此前，先诺欣临床前、I期、Ib期临床研究结果已在2023年7月至10月间先后于《柳叶刀》子刊、《自然》子刊等知名学术期刊发表。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1057642.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biontech.de","stockEarnings":[{"period":"1week","weight":0.0196},{"period":"1month","weight":-0.0528},{"period":"3month","weight":-0.0909},{"period":"6month","weight":-0.0341},{"period":"1year","weight":-0.229},{"period":"ytd","weight":-0.1653}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.0356},{"period":"6month","weight":0.2307},{"period":"1year","weight":0.2446},{"period":"ytd","weight":0.0633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学，尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究，开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制，利用各种生物学靶点，利用每位患者免疫系统的力量，解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.036134},{"month":2,"riseRate":0.2,"avgChangeRate":-0.029347},{"month":3,"riseRate":0.8,"avgChangeRate":0.158218},{"month":4,"riseRate":0.2,"avgChangeRate":0.0446},{"month":5,"riseRate":0.75,"avgChangeRate":0.0559},{"month":6,"riseRate":0.75,"avgChangeRate":0.096187},{"month":7,"riseRate":1,"avgChangeRate":0.203321},{"month":8,"riseRate":0.5,"avgChangeRate":-0.066227},{"month":9,"riseRate":0.25,"avgChangeRate":-0.052386},{"month":10,"riseRate":0.75,"avgChangeRate":0.033872},{"month":11,"riseRate":1,"avgChangeRate":0.26222},{"month":12,"riseRate":0.4,"avgChangeRate":-0.023804}],"exchange":"NASDAQ","name":"BioNTech SE","nameEN":"BioNTech SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}